Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?

被引：0
|
作者：
Pujol Muncunill, G. [1 ]
Martinez-Osorio, J. [1 ]
Bossacoma-Busquets, F. [2 ]
Alvarez-Carnero, L. [1 ]
Arrojo-Juarez, J. [2 ]
Vila-Miravet, V. [1 ]
Martin De Carpi, F. J. [1 ]
机构：
[1] Hosp St Joan de Deu, Unit Comprehens Care Pediat Inflammatory Bowel Di, Dept Pediat Gastroenterol Hepatol & Nutr, Esplugues Del Llobregat, Spain
[2] Hosp St Joan de Deu, Pharm Dept, Esplugues Del Llobregat, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P407
引用
收藏
页码：S375 / S375
页数：1
相关论文
共 50 条
  • [31] The usefulness of splitting tablets as a cost-saving strategy is limited
    不详
    Drugs & Therapy Perspectives, 2003, 19 (7) : 21 - 24
  • [32] Thin palladium layers: An effective cost-saving strategy
    1600, PennWell Corporation (28):
  • [33] A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease
    Miehsler, W.
    Novacek, G.
    Wenzl, H.
    Vogelsang, H.
    Knoflach, P.
    Kaser, A.
    Dejaco, C.
    Petritsch, W.
    Kapitan, M.
    Maier, H.
    Graninger, W.
    Tilg, H.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2010, 4 (03): : 221 - 256
  • [34] COST EFFECTIVENESS OF A PROACTIVE THERAPEUTIC DRUG MONITORING STRATEGY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB
    Doherty, Jayne
    Varley, Rachel
    Kennedy, Una
    Healy, Martin
    Dunne, Cara
    Maccarthy, Finbar
    Mckiernan, Susan
    Hartery, Karen
    Kevans, David
    GASTROENTEROLOGY, 2021, 160 (06) : S692 - S693
  • [35] Cost Effectiveness of a Proactive Therapeutic Drug Monitoring Strategy in Patients with Inflammatory Bowel Disease Receiving Infliximab
    Doherty, J.
    Varley, R.
    Healy, M.
    Dunne, C.
    Mac Carthy, E.
    Mc Kiernan, S.
    Hartery, K.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S445 - S446
  • [36] Infliximab in inflammatory bowel disease
    Papamichael, Konstantinos
    Lin, Steve
    Moore, Matthew
    Papaioannou, Garyfallia
    Sattler, Lindsey
    Cheifetz, Adam S.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10
  • [37] ARE DISEASE MANAGEMENT PROGRAMS FOR COPD COST-SAVING?
    Boland, M. R. S.
    Tsiachristas, A.
    Kruis, A.
    Chavannes, N.
    Rutten-van Molken, M. P. M. H.
    VALUE IN HEALTH, 2012, 15 (07) : A566 - A566
  • [38] Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models
    Heikal, Omnia Salah
    van Rheenen, Patrick F.
    Touw, Daan J.
    Kosterink, Jos G. W.
    Maurer, Marina
    Koomen, Jeroen V.
    Chelle, Pierre
    Mian, Paola
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (09) : 2200 - 2214
  • [39] Infliximab in paediatric inflammatory bowel disease (vol 1, pg 2, 2007)
    Vilar, P.
    JOURNAL OF CROHNS & COLITIS, 2008, 2 (02): : 189 - 189
  • [40] Subcutaneous infliximab use in children with inflammatory bowel disease in a tertiary paediatric hospital
    Eldredge, Jessica A.
    Chuah, Cher Wei
    Tano, Michelle
    Chidgey, Trudy
    Singh, Noel
    Thacker, Kunal
    Magoffin, Annabel
    Dutt, Shoma
    O'Loughlin, Edward
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 328 - 329
12345